Protein-protein interactions play key roles in leukocyte extravasation process into the brain and have been attractive therapeutic targets for inhibiting brain...
The FASEB Journal, Wiley, mars 2022, Volume : 36, Numéro : 3
The blood-brain barrier (BBB) prevents the majority of drugs from crossing into the brain and reaching neurons. To overcome this challenge, safe and...
Antibody-based therapeutics have emerged as novel class of biopharmaceuticals over the last couple of decades with the advancements made in production and...
Fluids and Barriers of the CNS, BMC, 26 mai 2023, Volume : 20, Numéro : 1
Blood brain barrier (BBB) models in vitro are an important tool to aid in the pre-clinical evaluation and selection of BBB-crossing therapeutics. Stem cell...
The FASEB Journal, Federation of American Society of Experimental Biology, 2 avril 2020, Volume : 34, Numéro : 6
Prolonged serum half-life is required for the efficacy of most protein therapeutics. One strategy for half-life extension is to exploit the long circulating...
Journal of Cerebral Blood Flow & Metabolism, 23 juin 2016
Cerebrovascular insufficiency appears years prior to clinical symptoms in Alzheimer’s disease. The soluble, highly toxic amyloid-β species, generated from the...
The blood‐brain barrier (BBB) is a formidable obstacle to the delivery of therapeutics to the brain. Antibodies that bind transferrin receptor, which is...
Lentiviral vectors (LVs) are a powerful tool for gene and cell therapy and human embryonic kidney cells (HEK293) have been extensively used as a platform for...
Article de périodique (revue)
Texte intégral en ligne
Filtrer vos résultats
Opération réussie
L’élément a été sauvegardé.
Opération réussie
Cet élément a été retiré.
Erreur
Vous avez dépassé le nombre maximal de 100 résultats sauvegardés.
Erreur
Impossible de sauvegarder l’élément. Veuillez réessayer. Si le problème persiste, il pourrait y avoir un problème avec l’élément.
Erreur
Impossible de supprimer l’article demandé. Veuillez réessayer plus tard.